Research and license agreement with Wyeth
14th Nov 2006, 05:38 GMT
Ablynx enters deal with Wyeth Pharmaceuticals to discover, develop and commercialise Nanobodies directed at the tumour necrosis factor alpha protein and its receptors
Research and license agreement with Wyeth related news:
- Wyeth s Time of Presentation at the Credit Suisse 1st Boston Healthcare Conference — Bio-Technology News from StratCenter.com
- Apple Changes the APSL Rules — Slashdot: Apple
- Apple changed APSL — Hack In The Box
- Epson and Microsoft In Cross-License Agreement — CdrInfo.com Just Published News
- Intelligent Medical Objects and Bond Technologies Sign Multi-year Agreement — StratWire - Business of Healthcare NewsFeed
- Boston Scientific and Univ of Akron Expand License Agreement for Use of UA Polymers in Medical Devices — StratWire - Business of Healthcare NewsFeed
- Client Security Public Beta EULA — NT Compatible
- NutriOne Corporation: NutriOne Announces a New Licensing Agreement With Dairy Fresh Farms Inc. for Canada — Market Wire - Energy and Utilities
- Boston Scientific and University of Akron Expand License Agreement for Use of UA Polymers in Medical Devices — PR Newswire: All Releases
- Qualcomm's in the chips with Motorola agreement London announcement also touches on plans — SignOnSanDiego.com: Business
Latest news from Services latest news on Laboratorytalk:
- New CEO for Fusion Antibodies
- Sponsor of two awards in IChemE programme
- InforSense announces conference series
- 2007 course catalogue covers latest techniques
- E-learning on physical chemistry of polymers
- New scholarship programme at Sartorius
- The changing landscape for needle-free injection
- Nitric oxide: NO news is good news
- Mass spec breakfast seminar in Massachusetts
- Challenges and opportunities in global health